AIMM Therapeutics

AIMM Therapeutics focuses on the discovery and development of innovative antibody-based therapeutics, utilizing advanced proprietary platform technologies to target various diseases effectively. Founded in 2004 and headquartered in Amsterdam, Netherlands, AIMM Therapeutics specializes in developing antibody-based therapies. The company has secured a EUR 2. 9 mn Grant from Agentschap NL in September 2013.

The founder, Donald Kalff, has previously founded other ventures, contributing to the company's strategic direction under current CEO Jeroen Sparla. AIMM Therapeutics develops antibody-based therapeutics using proprietary technologies including Kling-Select and Kling-Evolve. Their approaches have led to the identification of therapeutic targets and fully human antibodies from patient-derived B cells. Their notable products include nirsevimab/Beyfortus™, with a focus on addressing infectious diseases and cancer treatment.

AIMM Therapeutics generates revenue through partnerships and collaborations with pharmaceutical companies, licensing its proprietary technologies and therapeutic candidates. This includes milestone payments from successful clinical trials and potential royalties on product sales, particularly from its flagship product, nirsevimab/Beyfortus™, which underscores its capability to deliver market-ready solutions. AIMM Therapeutics plans to leverage the recent EUR 2. 9 mn funding to support ongoing development of new antibody therapeutics.

The company aims to expand its product offerings, particularly in oncology, while targeting broader international markets for its innovative therapies. Specific timelines for product launches and geographical expansion have not been disclosed, but the company is poised for strategic growth in its therapeutic areas.